logo-loader
RNS
Optima Health PLC

Optima Health PLC - Full Year Trading Update

RNS Number : 3834I
Optima Health PLC
16 June 2026
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

Optima Health plc

("Optima", the "Company", and, together with its subsidiaries, the "Group")

 

Full Year Trading Update

 

LONDON, UK, 16 June 2026, Optima Health (AIM: OPT), the UK's leading provider of technology enabled corporate health and wellbeing solutions, today announces an unaudited trading update ahead of the publication of the Group's results for the year ended 31 March 2026.

Highlights

·    Revenue for the year of approximately £121 million; 15% growth year-on-year (FY25: £105 million) in line with market expectations

·    Other income of £4.7 million recognised relating to a previously disclosed procurement matter

·    FY26 adjusted EBITDA expected to be c.10% ahead of previous market expectations as previously announced

·    Completion of transformational £100 million acquisition of PAM Healthcare Limited ("PAM") on 26 March 2026, significantly enhancing scale and capability of the Group

·    Integration activity is well underway with annualised synergies of £1.3 million already delivered as of 1 June 2026

·    New business annualised wins of £10.8 million in FY26 [Optima only](FY25: £27.2 million) with a strong pipeline of new potential opportunities across the enlarged group including PAM

·    Robust balance sheet with net debt (excluding leases) of £94.4 million as at 31 March 2026

 

Optima expects to report revenue for the full year of approximately £121 million, in line with market expectations, representing 15% growth versus FY25. As previously communicated, Optima expects FY26 adjusted EBITDA to be approximately 10% ahead of previous market expectations. Reflecting completion of the acquisition of PAM shortly prior to the year ended, the Group's net debt position (excluding leases) at 31 March 2026 was £94.4 million, comprising a cash balance of £21.6 million and £116 million of debt. Net debt at the end of May has reduced following repayment of the £30 million shareholder bridging loan associated with the acquisition of PAM, using net proceeds from the underwritten Open Offer equity raise which completed on 24 April 2026.

The Group has continued to make strong progress against its strategic objectives and medium‑term targets of achieving annual revenues of £200 million and £40 million of adjusted EBITDA. In line with the Group's strategy, Optima completed the transformational acquisition of PAM in March 2026 for total cash consideration of approximately £100 million. As one of the UK and Republic of Ireland's leading occupational health and wellness service providers, PAM is highly complementary and synergistic to Optima's existing operations. The integration of PAM is proceeding to plan and is expected to deliver significant revenue synergies, alongside operational and cost efficiencies. As of 1 June 2026 £1.3 million of annualised cost synergies have already been delivered.

The acquisition of PAM followed two strategic acquisitions by Optima during the first half of the year to further accelerate long-term growth and continue to increase the Group's market share, and broaden its capabilities, both in scope and geography.

Optima expects to report its Full Year Results for the year ended 31 March 2026 in August 2026.

 

Jonathan Thomas, Chief Executive Officer of Optima Health, said: "Optima's performance in FY26 demonstrates the momentum we are building as we deliver against our strategic objectives. Completing the acquisition of PAM during the year has expanded our capabilities and strengthened our ability to support customers across the UK and Ireland. As we look ahead, our priorities remain clear: maintaining high quality service delivery, progressing integration activities and our transformation programme, and advancing strategic initiatives to support the next phase of growth towards our stated ambition."

 

 

 

Enquiries

 

Optima Health

Jonathan Thomas, CEO

Heidi Giles, CFO

 

+44(0) 33 0008 5113

media@OptimaHealth.co.uk

Nominated Adviser and Joint Corporate Broker

Panmure Liberum Limited

Emma Earl / Will Goode/ Mark Rogers /

Rupert Dearden

Debt Advisory (sole debt adviser on the transaction):

Dan Howlett / Ben Handler

 

 

+44 (0)20 3100 2000

Joint Corporate Broker

Cavendish Capital Markets

Geoff Nash / Ben Jeynes / George Lawson /

Julian Morse / Michael Johnson/ Nigel Birks

 

+ 44 (0)20 7220 0500

 

UK Financial PR Adviser

ICR Healthcare

Mary-Jane Elliott / Angela Gray / Lindsey Neville

optimahealth@icrinc.com

 


 

 

About Optima Health

 

Optima Health is the UK's leading provider of occupational health and wellbeing services, delivering clinically led, technology-driven solutions to organisations across the public and private sectors. With a team of more than 1,600 including 800 clinicians, Optima Health supports millions of employees and operates from a network of more than 50 clinics nationwide.

 

In addition to its core UK market, Optima Health also operates in Ireland under Optima Health Ireland, providing occupational health services to clients nationwide.

 

For more information visit www.optimahealth.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKPBBCBKDOAD
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Optima Health, Impact Healthcare REIT, Seeing Machines, ATOME, Tertiary...

Optima Health PLC (AIM:OPT, OTC:OHLTF, FRA:J3N) says it's starting the new year with strong momentum and sticking to its growth targets. It's chasing £200 million in revenue, backed by a huge new Armed Forces recruitment contract worth up to £210 million. Read more Impact Healthcare REIT PLC...

on 08/17/2026

5 min read